Loading viewer...
investor_presentation
Format: PDF investor_presentation
UCB’s strong performance enables continued investment into future growth drivers 25 July 20192019 Half Year Results
UCB’s strong performance
enables continued investment into future growth drivers
25 July 20192019 Half Year ResultsDisclaimer and safe harbor
Forward -looking statements
This presentation contains forward- looking statements, including, without limitation, statements containing the words “believes” , “anticipates”, “expects”, “intends”,
“plans”, “seeks”, “estimates”, “may”, “will”, and “continue” and similar expressions. These forward- looking statements are based on current plans, estimates and beliefs
of management. By their nature, such forward- looking statements are not guarantees of future performance and are subject to know n and unknown risks,
uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, orindustry results, to be materially
different from any future results, performance, or achievements expressed or implied by such forward- looking statements contained in this presentation.
Important factors that could result in such differences include but are not limited to: changes in general economic, business and competitive conditions, the inability to
obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with res earch and development, changes in
the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims,
competition from other products including biosimilars, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange
rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its em ployees. There is no guarantee that new
product candidates will be discovered or identified, nor that such product candidates in the pipeline will progress to produc t approval or that new indications for existing
products will be developed and approved. Preclinical results also do not guarantee safe and effective performance of product candidates in humans. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disput es between the partners or may not be as
safe or effective as UCB believed at the time of entering into such relationship. Also, UCB or others could discover safety, sid e effects or manufacturing problems with
its products after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products t hatimplicate an entire class of products
may have a material adverse effect on sales of the affected products. Moreover, sales may be impacted by international and domes tic trends toward managed care
and health care cost containment, including pricing pressure, political and public scrutiny and the reimbursement policies im posed by third- party payers as well as
Preview truncated — download the full document for the complete content.
investor_presentation
10 Pages
Vitesse Energy, Inc.